Tenax Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Tenax Therapeutics

09/05/2025 15:34

Tenax Therapeutics Inc TENX.OQ TENX.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Tenax Therapeutics Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Tenax Therapeutics Inc is $20.00​, above​ its last closing price of $5.82. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.15
-0.42
-0.18
Beat
57.4
Sep. 30 2024
-1.40
-1.39
-0.19
Beat
86.3
Jun. 30 2024
-1.99
-1.98
-1.83
Beat
7.8​
Mar. 31 2024
-2.48
-2.40
-3.12
Missed
-30
​​Dec. 31 2023
-8.11
-8.14
-12.98
Missed
-59.4
Sep. 30 2023
-4.80
-7.20
-6.40
Beat
11.1​
Jun. 30 2023
-7.90
-8.00
-4.00
Beat
50
Mar. 31 2023
-29.60
-29.60
-12.00
Beat
59.5

This summary was machine generated May 9 at 14:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)